2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2517

Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders
Abstract Number: 2645

Long-Term Efficacy and Safety of Pulse Cyclophosphamide for Neuropsychiatric Systemic Lupus Erythematosus: A Two-Centre Experience
Abstract Number: 1674

Long-Term Efficacy of Rituximab in Systemic Sclerosis
Abstract Number: 957

Long-Term Evaluation of NT-Probnp Levels in Ankylosing Spondylitis Patients Under TNF Blockers: A Marker of Persistent Disease Activity?
Abstract Number: 1782

Long-Term Follow-up of Non-HBV Polyarteritis Nodosa and Microscopic Polyangiitis with Poor-Prognosis Factors
Abstract Number: 298

Long-Term Impact of Juvenile Idiopathic Arthritis in the Greek adults’ Psychosocial Life
Abstract Number: 49

Long-Term Oral Bisphosphonate Use for Osteoporosis Among Older Women – US and Canadian Perspective
Abstract Number: 2763

Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease
Abstract Number: 1781

Long-Term Outcomes Among Patients with Renal Disease Secondary to ANCA-Associated Vasculitis: Temporal Trends over 25 Years
Abstract Number: 813

Long-Term Outcomes of Takayasu’s Arteritis Patients with Renal Artery Involvement
Abstract Number: 294

Long-Term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 1159

Long-Term Quality of Life, Productivity Impairment, Disease Severity and Health Care Costs in Relation to Functional Impairment in Ankylosing Spondylitis Patients in the Czech Republic
Abstract Number: 273

Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis
Abstract Number: 545

Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure
Abstract Number: 2505

Long-Term Treatment with Tocilizumab (TCZ) Strongly Suppresses Joint Destruction in Biologic-naïve Patients with Rheumatoid Arthritis (RA) Regardless of Inflammation Status

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].